Search tips
Search criteria 


Logo of jbreasthealthThe Journal of Breast Health
J Breast Health (2013). 2016 January; 12(1): 1–8.
Published online 2016 January 1. doi:  10.5152/tjbh.2015.2711
PMCID: PMC5351429

Male Breast Cancer


Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancer diagnoses worldwide. Although breast carcinomas share certain characteristics in both genders, there are notable differences. Most studies on men with breast cancer are very small. Thus, most data on male breast cancer are derived from studies on females. However, when a number of these small studies are grouped together, we can learn more from them. This review emphasizes the incidence, etiology, clinical features, diagnosis, treatment, pathology, survival, and prognostic factors related to MBC.

Keywords: Breast cancer, male gender, review


Over the past two decades, major improvements have been achieved in the understanding of breast cancer, and cure can be offered if the disease is diagnosed at an early stage. However, the disease is more often diagnosed at more advanced stages (3 or 4) in men, in contrast to women. Its rarity among men as well as lack of awareness leads to its detection at later stages. Randomized studies cannot be carried on due to the low incidence of breast cancer in males, with only a few published prospective therapeutic studies in the literature. While the information on male breast cancer (MBC) was obtained from retrospective studies, the recommendations for treatment were derived from studies conducted on female breast cancer (1). This review presents the frequency, etiology, clinical-pathological characteristics and treatment approaches for the rare MBC.


Male breast cancer is rare and constitutes 0.5–1% of all patients with breast cancer. The reason of the low incidence rate in men is the relatively low amount of breast tissue along with the difference in their hormonal environment. Even though breast tissue is less in men as compared to women, the factors that influence malignant changes are similar. The Surveillance, Epidemiology and End Result (SEER) Program reported that the incidence of breast cancer was highest at ages 52–71 during 1973–2000, whereas the peak incidence in males was 71 years (2). In fact, some authors state that MBC imitate the behavioral pattern of post-menopausal female breast cancer. The incidence of breast cancer in males and females has increased in the past 25 years. International Association of Cancer Registries (IACR) emphasized this increase and stated that the incidence of female breast cancer increased by 20%, while breast cancer-related deaths increased by 14%. The SEER data also showed that the rate that was 1.1 for 100.000 men in the mid-1970s and raised to 1.44 for 100.000 men by 2010 (3). In USA, 2240 men were diagnosed with breast cancer within the year 2013. The lifetime rate of diagnosis with male breast cancer is 1 in 1000. According to the IACR Turkey data, 0.37% of all cancer types among males are breast cancer (4, 5). IACR has published its new cancer estimates for the year 2012. The most recent cancer estimates for 28 cancer types in 184 countries, which record cancer data, have been made available for users on the GLOBOCAN 2012 website (6).

The rate of presentation with advanced stage breast cancer has been decreasing in men. As a matter of fact, a study conducted in 1995 reported the rate of Stage 1–2 disease on diagnosis as 70%, whereas it was reported as 67% in 2010 and 82% in 2015 (79). MBC constitutes less than 1% of male cancers and it has a varying rate of incidence across different geographies and ethnic groups (10, 11). Its annual prevalence in Europe is 1 in 10.000 men and these cases constitute less than 1% of all patients with breast cancer (4). However, this rate is above 6% in Central African countries (12). This relatively higher rate is attributed to liver damage and to endemic infectious diseases that lead to high levels of estrogen. In Japan, the annual MBC incidence is below five in a million (13). The only race where MBC incidence is above the average is the Jewish men and this characteristic is independent from living in the USA or Israel (14, 15). Based on our current knowledge, there is no convincing evidence that gynecomasty is associated with MBC; however, it is considered that it may be associated with shared hormonal risk factors (10). Breast cancer may be incidentally found in the specimens of cases operated on for gynecomasty, whereas gynecomasty may be found in the specimens of cases operated on for breast cancer (at a rate of 9% to 40%) (16, 17). It is reported that 6% to 38% of patients with breast cancer have clinical gynecomasty. These rates are not different from those of the normal population (18). A positive family history increases the relative risk 2.5 times, and 20% of men with breast cancer have a first degree relative with the same disease (4, 19). While the relative risk for a first second male breast cancers 30 times higher, this rate is only around 2–4 times for women. The risk for breast cancer on the contra lateral side is the highest for those at or below the age of 50, as in women (20, 21).

The known risk factors for male breast cancer are listed in Table 1. The incidence is directly proportional to age. While the age difference between men and women at the time of diagnosis is higher in the USA, this difference is not that high in the Middle East and Southern Asia (22, 23). The risk factor of genetic predisposition in men is similar to that of women. Klinefelter syndrome is the strongest risk factor for MBC and it is seen in approximately one out of every 1000 men (10, 24, 25). Family history of breast cancer brings about a 2.5 times relative risk for men. Nearly 20% of men with breast cancer have a positive family history. BRCA mutations increase the risk for male breast cancer (26). The best-known genetic linkage to MBC is the BRCA2 mutation (27). BRCA1 mutation, however, has a more limited role in MBC. The presence of BRCA2 mutation in sporadic MBC is rare. MBC in patients with the mutation tends to present at a younger age. Similarly, breast cancer in men with Klinefelter Syndrome is detected in the young ages (18). The other genetic factors include androgen receptor (AR) gene, CYp17, PTEN tumor suppressor gene and CHEK2 mutation (28). Nearly 3% to 7.5% of MBC cases have Klinefelter syndrome (2830). In addition to BRCA1 and BRCA2, CHEK2 is a kinase effective in DNA repair. There is some evidence indicating that CHEK2 creates predisposition to male breast cancer (31).

Table 1
Risk factors for male breast cancer (3, 4, 9, 19, 2429,3235, 4247)

Several risk factors such as early menarche, late menopause, age at first live birth are still valid for female breast cancer, and are not applicable to men. Several studies evaluating risk factors for male breast cancer have been conducted. The prospective National Institute of Health (NIH)-AARP Diet and Health Study ultimately identified 121 men who developed breast cancer (5). In this analysis, a negative correlation with physical activity was established and having history of a first-degree relative with male breast cancer (relative risk, RR, 1.92; 95%CI 1.24–3.91) and increased body mass index (>30 vs. <25; RR 1.79, 95%CI 1.10–2.91) were found to correlate with increased breast cancer. The factors that influence the ratio of estrogen to androgen, external administration of estrogen or testosterone (32), obesity (29, 3335), orchitis/epididymitis (29), presence of a history of prostate cancer treated with estrogen (36) and Klinefelter Syndrome (25, 29) increase the risk of male breast cancer. Another study that analyzed the USA Veterans Affairs database detected 642 MBCs (29). The risk factors were found to be the presence of diabetes (RR 1.30, 95%CI 1.05–1.60), orchitis/epididymitis (RR 1.84, 95%CI 1.10–3.08), Klinefelter syndrome (RR 29.64, 95%CI 12.26–71.68) and gynecomasty (RR 5.86, 95%CI 3.74–9.17). Interestingly, gallbladder stone was also detected as an important risk factor for Afro-American MBC cases (RR 3.45, 95%CI 1.59–7.47). A very strong association between MBC and Klinefelter was observed in the Veteran study and in several other similar studies. For example, the Swedish Registry study reported a 50-times higher rate of breast cancer in those with Klinefelter Syndrome (25). History of liver disease, past breast and testicular pathologies are other risk factors that have been described (4).

More interestingly, the male breast cancer is stated to be a preliminary finding for other malignant processes. A review focusing on 69 male breast cancer cases identified simultaneous prostate cancer in 12 patients (17% of the cases examined) (37). Actually, there is a theoretical association; the aromatase inhibitor used in MBC treatment increases serum testosterone levels and enables the growth and proliferation of prostate cancer clones (38). Apart from prostate cancer, there are studies that support the association of MBC with leukemia, pancreas, small intestine and rectum malignancies (3941). Various epidemiologic studies have been performed (42), professional exposure to certain chemicals such as polycyclic aromatic hydrocarbons (4345) and electromagnetic field (46, 47) were detected as potential factors in the development of male breast cancer (4, 48, 49).

Symptoms, Clinical Signs and Manifestations

The most common presentations are painless palpable mass, skin ulceration, and nipple retraction or discharge in approximately 75% of the cases, similar to women (7, 5053). Since the breast tissue in men is undersized, the nipple is mostly involved at early stages. The incidence of retraction is 9%, discharge 6% and ulceration is 6% (10). The mass is frequently localized to the subareolar region. It is seen less frequently in the upper outer quadrant (54, 55). The left breast is involved more frequently than the right; 1% of the cases are bilateral.

Male patients are frequently at a higher age than female breast cancer (FBC) at diagnosis (5–10 years older) and at a higher stage (27, 5659).

The staging of the disease during presentation is as follows on the basis of the Tumor-Node-Metastasis (TNM) system presented by the largest case series in the literature: Stage 1: 37%, stage II: 21%, stage III: 33%, stage IV: 9% (51, 52, 60, 61). While the period between disease onset and diagnosis was 29 months in the past (62), this period has been reduced to 6 months in the newer series (63). It is evident that the disease is diagnosed at more advanced stages in men as compared to women. In fact, more than 40% of the patients are already at stage 3 or 4 when they present to the clinic. The lesser amount of breast tissue in men also results in the involvement of chest wall at an early stage. For that reason, it has also been stated that the TNM may not be appropriate for men (64).

Diagnostic Imaging Methods and Differential Diagnosis

The majority of lesions in the male breast are benign and gynecomasty constitutes most of these lesions. Within these, less than 1% is primary breast cancer. Even though male breast is relatively small, mammography (MG) is technically feasible and adds useful information to clinical examination (65). In the presence of a clinically suspicious lesion, MG should be preferred over ultrasonography (USG). Sensitivity and specificity of mammography are reported as 92% and 90%, respectively (66). A normal male breast is essentially composed of fat tissue and contains only a few secretory canals. It does not have Cooper ligaments, and has none or very little ductal and interlobular connective tissue. For that reason, it has a radiolucent appearance on mammography (67). The tumor is visualized on MG as a hyperdense, well defined, lobulated mass with spiculated margins or as a structural distortion. Microcalcification is observed less as compared to FBC; its tendency of clustering is low, and generally appears as wide, round and dispersed calcifications.

Doyle et al. (68) emphasized the radiologic and pathologic differences between male and female breast cancer in their review:

  1. The incidence of invasive lobular cancer and in-situ disease are lower in men as compared to women.
  2. Male breast cancer more frequently manifests itself as a locally advanced disease (skin and/or nipple involvement).
  3. MBCs are more often localized in the subareolar area, whereas FBCs are localized in the upper outer quadrant.
  4. Malignant calcifications in MBC are less frequent as compared to women.
  5. Since neoplastic papillary lesions appear as complex cystic lesions and simple cysts are rare in men, cystic lesions should be evaluated in detail.

Invasive cancers typically appear as solid lesions on USG. When suspicious changes are found in USG or MG, further evaluation is required for definitive diagnosis (69, 70). In patients with nipple discharge, an examination with smear may be needed. The extent of the disease should be evaluated via laboratory examination, pulmonary X-ray, bone scintigraphy and dominal computed tomography (CT) (71). Positron emission tomography - computed tomography (PET-CT) is better than PET or computed tomography (CT) alone for assessing the extent of the disease, and especially for accurately identifying small metastases and lymph node metastases as well as the response to chemotherapy (72).

A differential diagnosis should be made between gynecomasty and cancer in masses of the male breast. The most frequent benign mass of the breast, which may be unilateral or bilateral, is gynecomasty (73). It may be generally recognized through physical examination. Gynecomasty is characteristically symmetrical, bilateral and has a discoid shape under the nipple and areola. As for carcinoma, it develops a painless hard mass at an eccentric location. Besides breast cancer, the reasons that cause a mass in the male breast include gynecomasty, abscess, hematoma, lipoma, fat necrosis, ductal ectasia, intraductal papilloma, cyst, and metastatic tumors (74). Metastasis to the breast is generally 5–6 times more often in women as compared to men (approximately 0.5% to 6.6% of breast malignancies), which is accounted for by differences in hormonal and endothelial cell adhesion molecules, as well as in breast size and vascularity (75). The most frequent primary tumors in men, which metastasize to the breast include melanoma, lymphoma, prostate, lung and colon tumors (76).


Treatment of early-stage disease

The standard treatment for early stage male breast cancer is surgery followed by adjuvant endocrine treatment, chemotherapy (CT) or radiotherapy (RT) depending on prognostic factors, which is the same as in women.

Surgical treatment approach and axillary lymph node dissection

Up until the 1970s, the main surgical method was radical mastectomy as in women. Considering the lesion size, this approach was replaced by less invasive procedures such as modified radical mastectomy over time (7779). Currently, modified radical mastectomy and axillary lymph dissection or sentinel lymph node biopsy (SLNB) is recommended if the tumor is not fixed to the pectoral muscle (80). Actually, American Society of Clinical Oncology guidelines state that SLNB is appropriate for men (7). Radical mastectomy is performed if there is extensive involvement of the chest wall and Rotter ganglions (78). Breast-conserving surgery (lumpectomy) may be performed in elderly patients, with a serious concomitant disease, who has gynecomasty along with a small tumor since the male breast is small and most tumors have a subareolar location, but this procedure is rarely preferred (81). Adjuvant RT is also added to the treatment of such patients. Surgeries that are more radical do not contribute to survival. In cases with high tumor burden, preoperative CT may be useful. Patients with a metastatic disease or a poor overall condition may receive a combined treatment with simple mastectomy or local tumor excision with postoperative RT (82).

Radiotherapy (RT)

Radiotherapy is mandatory if breast-conserving surgery is performed (83). However, the data about RT indications following mastectomy are limited. RT is generally applied in case of involvement of the nipple and skin (84). Adjuvant loco-regional RT is performed more often in MBC than in women because of the more advanced stages and the more aggressive progress in males. Post-mastectomy RT decreases local recurrence by 2/3 in women and has a positive effect on long-term survival (85). On the other hand, it is suggested that post-mastectomy RT does not improve local recurrence and survival rates in MBC and that it enables local tumor control but does not influence overall survival (86, 87). However, there is no evidence showing that RT indications need to be different for men than those for women. In summary, RT is recommended in the presence of a positive lymph node, a tumor larger than 5 cm and margin positivity in MBC (71).

Chemotherapy (CT)

Excluding non-neoplastic reasons, primary and adjuvant chemotherapies have significantly increased the survival rates for 5–10 years (79). A limited number of prospective, randomized clinical studies exist, which indicate the benefit of adjuvant systemic therapy for MBC (88). On the other hand, decreased recurrence and mortality rates have been reported with adjuvant CT in retrospective studies (53, 89). Furthermore, the prognosis and response rates to therapy in with metastatic MBC are similar to those of women. For that reason, it is considered that early stage MBC patients would benefit from adjuvant therapy (77). There is not enough information about the poor prognostic factors according to which a decision for adjuvant CT could be taken. Usually, the prognostic factors that are used in women are applied to men. There is an indication for CT in those with positive lymph nodes, in tumors larger than 1 cm, and negative for hormone receptors (90, 55). Triple negativity (hormone receptors and HER2/neu negativity) is a sign of aggressiveness, this suggests a high-risk patient and is accepted as an indication for CT. HER2/neu and p53 expression are indicators for poor prognosis, and these patients may require a more aggressive systemic treatment. For node negative patients, anthracycline-based CT is preferred whereas anthracycline and taxane are used for those with positive lymph nodes. Based on the data from treatments in women, trastuzumab must be administered in case of HER2/neu positivity, in node-positive or high-risk node negative disease (10).

Adjuvant Endocrine Therapy

Adjuvant endocrine therapy alone or in combination with CT is recommended for MBC patients, based on the positive results in clinical studies on early-stage FBC patients. However, there are only a few retrospective studies on this issue with no randomized clinical trials. These studies also demonstrated decreased recurrence and mortality rates (77, 91). Most male patients are hormone-receptor (HR) positive, and either tamoxifen or another hormone therapy for 5 years is recommended to those with positive estrogen receptor according to their prognostic factors, similar to women (90). There are also studies defending that hormonal therapy should be the primary treatment method since MBC is rich in hormone receptors and is a cancer that is more sensitive to hormones, while other adjuvant therapies need to be administered in large tumors and positive axillary lymph nodes (92). Tamoxifen is the generally accepted medication for hormonal therapy. The role of aromatase inhibitors in adjuvant therapy is limited.

Treatment of locally advanced disease

The treatment of male patients with T3/T4 or inflammatory breast cancer is initiated with neo-adjuvant CT and surgery is performed on those whose tumor becomes amenable to operation. Subsequently, adjuvant tamoxifen is recommended for HR positive cases. It should also be kept in mind that adjuvant hormonal therapy may be an alternative to CT in most cases (93).

Treatment for advanced disease

Approach to metastatic breast cancer is based on the same principles in both men and women. Metastasis is identified at diagnosis in approximately 5–15% of MBC cases. Di Lauro et al. (94) reported that the most frequent location for metastasis visceral in 76% (lung, liver), bones in 20% and soft tissue (skin) in 4% of the cases in their series of 50 male breast cancer cases. For treating metastatic diseases orchiectomy, adrenalectomy and hypophysectomy have been performed in the past. Since the response rate of the more frequent HR-positive tumors to hormone therapy is 25% to 58%, tamoxifen is currently used as first-choice therapy in such tumors. CT is recommended if the tumor is unresponsive to hormonal therapy (95). Progestins, androgens and luteinizing hormone-releasing hormone agonists may be used in hormone therapy, albeit at a lower rate (55). The value of aromatase inhibitors such as anastrozole and letrozole in metastatic breast cancers has not been fully established. Systemic CT is used in male HR-negative patients with a rapidly progressing and life-threatening visceral disease. Although it is thought that trastuzumab may be useful in HER-2/neu positive disease, the data available on this issue is insufficient.


Male breast cancer is different from female breast cancers with respect to clinical-pathologic characteristics. Despite that, the diagnosis and treatment approaches are based on the results obtained in female breast cancers, since the data regarding MBC are mainly composed of retrospective, single-center case series rather than randomized clinical trials (56, 96, 97). Previous studies have demonstrated that the rate of HR positivity in MBC is higher and most patients are more sensitive to anti-hormonal treatment (27). Almost all histologic types pertaining to FBC have also been reported for MBC, with varying rates. According to the SEER data, 93.7% of MBC is ductal or unclassified, and only 1.5% is of the lobular sub-type (96). This rate is in contrast with those in women (12–15%) (54). This is due to the fact that the male breast tissue remains rudimentary. It is generally exposed to increased estrogen concentrations, is not differentiated and does not result in lobular formation. The tumor grade was detected as 12–20% Grade I, 54–58% Grade II and 17–33% Grade III tumors (43). The other histological types are papillary (2.6%) and mucinous (1.8%) tumors (54). MBC shows a higher estrogen and progesterone receptor expression as compared to women (90% ER, 81% PR in males vs. 60–70% ER or PR in females) (96). As for HER-2/neu expression, it is lower in men in comparison to women (55). The molecular subtypes of breast cancer in women have been widely studied in terms of immunohistochemistry and its importance has been proven (98100). Accordingly, normal breast-like, basal-like, luminal A, luminal B, and HER2-enriched subtypes have been identified. There is no consensus on molecular subtyping of male breast cancer, and the few studies with small group of patients yielded inconsistent results. In a study of 134 cases from multiple centers, Kornegoor et al. observed luminal type A as being the most frequent type with a rate of 75% (101). While luminal type B was the second most frequent type with 21%, the incidence rate of other types was only 4%. Tumors in luminal B subtype tend to have a higher nuclear degree (93). In another study conducted on 960 patients, the patient distribution was as follows: 84.9% HR-positive/HER2-negative, 11.5% HR− negative/HER2-positive, 0.6% HR-positive/HER2-positive and 2.9% Triple negative (102).

Prognosis, Survival and Prognostic Factors

Despite the decrease in mortality rate in female breast cancers, the mortality rate in MBC remained unchanged since 1975 (103). The most important prognostic indicator is the stage at diagnosis and lymph node involvement (Figure 1). The overall 5-year survival rate is around 40–65% (7, 52, 77, 104). However, when evaluated according to stage at diagnosis; the 5-year survival rate is 75–100% for stage 1, 50–80% for stage 2, and is decreased to 30–60% for stage 3 (52). Although several studies have stated that the prognosis was worse in MBC than in females, it was determined that there were no differences in the prognosis of the two genders when paired according to age and stage (105). A large study with more than 335 male patients found that if nodal status is used to compare MBC and FBC, then the prognosis was similar (106). The less favorable results in male patients are due to the more advanced stage at presentation as well as a higher mean age at presentation leading to more co-morbidity (52, 107). While estrogen-receptor (ER) positive tumors have a better prognosis, no such association has been shown for progesterone (68). HER2 positivity is a poor prognostic characteristic (108). It is reported that survival is shorter and prognosis is poor in basal-like and HER2+/ER− subtypes in comparison to other groups (109). A secondary cancer may develop in 9–12% of MBC cases during follow-up (74, 110). The incidence rate of bilateral breast cancer in men is low (111). In the presence of metastatic disease (bone, lung, liver, brain, etc.), the median survival is reported as 26.5 months (88).

Figure 1
(A) Overall (B) Relative survival in male and female breast cancer: Surveillance, Epidemiology- and End Results registry, 1973 to 1998 (n=2.537)


Breast cancer is a rare disease among men and the number of cases included in studies is small. It may be confounded with benign diseases, and both patients and physicians may underestimate its signs. Since its detection is delayed, the disease is usually at advanced stages at the time of diagnosis. Breast cancer behaves differently in males. There is a need for multi-center studies with more patients that focus on the treatment, prognosis, tumor biology and parameters influencing survival.


Author Contributions: Concept - M.B.; Design - M.Y, A.İ., M.B.; Supervision - A.İ.; Data Collection and/or Processing- M.Y.; Analysis and/or Interpretation - M.Y.; Literature Review - M.Y.; Writing - M.Y.; Critical Review - M.Y., A.İ., M.B.

Peer-review: Externally peer-reviewed.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.


1. Giardano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10:471–479. [PubMed]
2. Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR, Raptis G, Hershman DL. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol. 2007;25:1089–1098. [PubMed]
3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program SEER Cancer Statistics Review, 1975–2011. Available from:
4. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer. 1993;53:538–549. [PubMed]
5. Brinton LA, Richesson DA, Gierach GL, Lacey JV, Park Y, Hollenbeck AR, Schatzkin A. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008;100:1477–1481. [PMC free article] [PubMed]
6. International Agency for Research on Cancer. GLOBOCAN 2012. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from:
7. Cutuli B, Lacroze M, Dilhuydy JM, Velten M, De Lafontan B, Marchal C, Resbeut M, Graic Y, Campana F, Moncho-Bernier V. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995;31A:1960–1964. [PubMed]
8. Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H, de Lara CT, Edeline J, Penault-Llorca F, Romestaing P, Delva C, Comet B, Belkacemi Y. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol. 2010;73:246–254. [PubMed]
9. Oger AS, Boukerrou M, Cutuli B, Campion L, Rousseau E, Bussières E, Raro P, Classe JM. Male breast cancer: prognostic factors, diagnosis and treatment: a multi-institutional survey of 95 cases. Gynecol Obstet Fertil. 2015;43:290–296. [PubMed]
10. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367:595–604. [PubMed]
11. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:20–26. [PubMed]
12. Public-use data (1993–1997) Bethesda (MD): National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2000. Surveillance, Epidemiology, and End Results (SEER) Program.
13. Waterhouse J, Muir C, Correa P, Powell JR, editors. Cancer incidence in five continents. Vol. 3. IARC Sci Publ; 1976. p. 15.
14. Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst. 1985;74:371–375. [PubMed]
15. Steinitz R, Katz L, Ben-Hur M. Male breast cancer in Israel: selected epidemiologic aspects. J Med Sci. 1981;17:816–821. [PubMed]
16. Atalay C, Kanlioz M, Altinok M. Prognostic factors affecting survivalin male breast cancer. J Exp Clin Cancer Res. 2003;22:29–33. [PubMed]
17. Koç M, Polat P. Epidemiology and aetiological factors of male breast cancer: a ten years retrospective study in eastern Turkey. Eur J Cancer Prev. 2001;10:531–534. [PubMed]
18. Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M. CHEK2 1100del C and male breast cancer in the Netherlands. Breast Cancer Res Treat. 2009;116:397–400. [PubMed]
19. Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factorsfor male breast cancer - a case-control study from Scandinavia. Acta Oncol. 2001;40:467–471. [PubMed]
20. Agrawal A, Ayantunde A, Rampaul R, Robertson JFR. Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2007;103:11–21. [PubMed]
21. Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer followingbreast cancer in men. J Natl Cancer Inst. 2002;94:1330–1332. [PubMed]
22. Salehi A, Zeraati H, Mohammad K, Mahmoudi M, Talei AR, Ghaderi A, Imanieh MH, Fotouhi A. Survival of male breast cancer in Fars, South of Iran. Iran Red Crescent Med J. 2011;13:99–105. [PMC free article] [PubMed]
23. Tawil AN, Boulos FI, Chakhachiro ZI, Otrock ZK, Kandaharian L, El Saghir NS, Abi Saad GS. Clinicopathologic and immunohistochemical characteristics of male breast cancer: a single center experience. Breast J. 2012;18:65–68. [PubMed]
24. Harnden DG, Maclean N, Langlands AO. Carcinoma of the breastand Klinefelter’s syndrome. J Med Genet. 1971;8:460–461. [PMC free article] [PubMed]
25. Hultborn R, Hanson C, Kopf I, Verbiené I, Warnhammar E, Weimarck A. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res. 1997;17:4293–4297. [PubMed]
26. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 2000;92:1126–1135. [PubMed]
27. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678–687. [PubMed]
28. Lynch HT, Watson P, Narod SA. The genetic Epidemiology of male breast carcinoma. Cancer. 1999;86:744–746.<744::AID-CNCR4>3.3.CO;2-7. [PubMed]
29. Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G. Etiologic factors for male breast cancer in the US Veterans Affairs medical care system database. Breast Cancer Res Treat. 2010;119:185–192. [PMC free article] [PubMed]
30. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27:1250–1256. [PubMed]
31. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR. CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2 (*) 1100del C in non-carriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55–59. [PubMed]
32. Medras M, Filus A, Jozkow P, Winowski J, Sicinska-Werner T. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat. 2006;96:263–265. [PubMed]
33. Altinli E, Gorgun E, Karabicak I, Uras C, Unal H, Akcal T. Anthropometric measurements in male breast cancer. Obesity surgery. 2002;12:869–870. [PubMed]
34. Casagrande JT, Hanisch R, Pike MC, Ross RK, Brown JB, Henderson BE. A case-control study of male breast cancer. Cancer Res. 1988;48:1326–1330. [PubMed]
35. Hsing AW, McLaughlin JK, Cocco P, Co Chien HT, Fraumeni JF., Jr Risk factors for male breast cancer (United States) Cancer Causes Control. 1998;93:269–275. [PubMed]
36. Thellenberg C, Malmer B, Tavelin B, Grönberg H. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol. 2003;169:1345–1348. [PubMed]
37. Lee UJ, Jones JS. Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening. Prostate Cancer Prostatic Dis. 2008;12:52–56. [PubMed]
38. Terris MK, McCallum SW. Re: Aromatase Inhibitors for Male Infertility. J Urol. 2002;168:1509. [PubMed]
39. Grenader T, Goldberg A, Shavit L. Second cancers in patients with malebreast cancer: a literature review. Journal of Cancer Survivorship. 2008;2:73–78. [PubMed]
40. Lowe T, Luu T, Shen J, Bhatia S, Shibata S, Stein A, Somlo G. Malebreast cancer 15 years after allogeneic hematopoietic cell transplantationincluding total body irradiation for recurrent acute lymphoblastic leukemia. Onkologie. 2008;31:266–269. [PubMed]
41. Unek IT, Alacacioglu A, Tarhan O, Sevinc AI, Oztop I, Sagol O, Canda T, Obuz F, Balci P, Yilmaz U. Synchronous appearance of male breast cancerand pancreatic cancer 15 years after the diagnosis of testicular cancer--report of a case. J BUON. 2008;13:421–424. [PubMed]
42. Rosenbaum PF, Vena JE, Zielezny MA, Michalek AM. Occupationalexposures associated with male breast cancer. Am J Epidemiol. 1994;139:30–36. [PubMed]
43. Hansen J. Elevated risk for male breast cancer after occupational exposure to gasoline and vehicular combustion products. Am J Ind Med. 2000;37:349–352. [PubMed]
44. Palli D, Masala G, Mariani-Costantini R, Zanna I, Saieva C, Sera F, Decarli A, Ottini L. A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer? Eur J Cancer. 2004;40:2474–2479. [PubMed]
45. Villeneuve S, Cyr D, Lynge E, Orsi L, Sabroe S, Merletti F, Gorini G, Morales-Suarez-Varela M, Ahrens W, Baumgardt-Elms C, Kaerlev L, Eriksson M, Hardell L, Févotte J, Guénel P, et al. Occupation and occupational exposure to endocrine disrupting chemicals in male breast cancer:a case-control study in Europe. Occup Environ Med. 2010;67:837–844. [PMC free article] [PubMed]
46. Matanoski GM, Breysse PN, Elliott EA. Electromagnetic field exposure and male breast cancer. Lancet. 1991;337:737. [PubMed]
47. Tynes T, Andersen A. Electromagnetic fields and male breast cancer. Lancet. 1990;336:1596. [PubMed]
48. Stenlund C, Floderus B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: a Swedish case-controlstudy. Cancer Causes Control. 1997;8:184–191. [PubMed]
49. Cocco P, Figgs L, Dosemeci M, Hayes R, Linet MS, Hsing AW. Case-control study of occupational exposures and male breast cancer. Occup Environ Med. 1998;55:599–604. [PMC free article] [PubMed]
50. Treves N, Holleb AJ. Cancer of the male breast. A report of 136 cases. Cancer. 1955;8:1239–1259. [PubMed]
51. Scheike O. Male breast cancer. Acta Pathol Microbiol Scand. 1975:3–35. [PubMed]
52. Ribeiro GG, Swindell R, Harris M, Baerjee S, Cramer A. A review of themanagement of the male breast carcinoma based on an analysis of 420treated cases. Breast. 1996;5:141–146.
53. Stierer M, Rosen H, Weitensfelder W, Hausmaninger H, Teleky B, Jakesz R, Fruhwirth H, Dünser M, Beller S, Haid A. Male breast cancer: Austrian experience. World J Surg. 1995;19:687–693. [PubMed]
54. Giordano SH. A review of the diagnosis and management of male breastcancer. Oncologist. 2005;10:471–479. [PubMed]
55. Sabel MS. Breast cancer in special populations. In: Sabel MS, editor. Surgical Foundations: Essentials of Breast Surgery. 1st ed. Philadelphia: Mosby Elsevier; 2009. pp. 323–333.
56. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol. 2008;16(6):58. [PMC free article] [PubMed]
57. Park S, Kim JH, Koo J, Park BW, Lee KS. Clinicopathological characteristics of male breast cancer. Yonsei Med J. 2008;49:978–986. [PMC free article] [PubMed]
58. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast Cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004;83:77–86. [PubMed]
59. Dong C, Hemminki K. Second primary breast cancer following breastcancer in men. Breast Cancer Res Treat. 2001;66:171–172. [PubMed]
60. van Geel AN, van Slooten EA, Mavrunac M, Hart AAl. A retrospective study of male breast cancer in Holland. Br J Surg. 1985;72:724–727. [PubMed]
61. Ramantanis G, Besbeas S, Garas JG. Breast cancer in the male: a report of 138 cases. World J Surg. 1980;4:621–624. [PubMed]
62. Sachs MD. Carcinoma of the male breast. Radiology. 1941;37:458–467.
63. Wagner JL, Thomas CR, Koh WJ, Rudolph RH. Carcinoma of the male breast: Update 1994. Med Pediatr Oncol. 1995;24:123–132. [PubMed]
64. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males. Cancer. 1998;83:498–509. [PubMed]
65. Chen L, Chantra PK, Larsen LH, Barton P, Rohitopakarn M, Zhu EQ, Bassett LW. Imaging characteristics of malignant lesions of the male breast. Radiographics. 2006;26:993–1006. [PubMed]
66. Evans GF, Anthony T, Turnage RH, Schumpert TD, Levy KR, Amirkhan RH, Campbell TJ, Lopez J, Appelbaum AH. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg. 2001;181:96–100. [PubMed]
67. Michels LG, Gold RH, Arndt RD. Radiography of gynecomastia and other disorders of the male breast. Radiology. 1977;122:117–122. [PubMed]
68. Doyle S, Steel J, Porter G. Imaging male breast cancer. Clin Radiol. 2011;66:1079–1085. [PubMed]
69. Jackson VP, Gilmor RL. Male breast carcinoma and gynecomastia: comparison of mammography with sonography. Radiology. 1983 Nov;149(2):533–6. [PubMed]
70. Kapdi CC, Parekh NJ. The male breast. Radiol Clin North Am. 1983;21:137–148. [PubMed]
71. NCCN Clinical Practice Guidelines in Oncology. Invasive Breast Cancer(v. 3.2015) Available at:
72. Yang SK, Cho N, Moon WK. The Role of PET/CT for Evaluating Breast Cancer. Korean J Radiol. 2007;8:429–437. [PMC free article] [PubMed]
73. Gill MS, Kayani N, Khan MN, Hasan SH. Breast diseases in males a morphological review of 150 cases. J Pak Med Assoc. 2000;50:177–179. [PubMed]
74. Eser S. Kanser Kayıtçılığı ve Kanser Kayıt Merkezleri. In: Tuncer M, editor. Türkiye’de Kanser Kontrolü. T.C.Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı Yayınları; 2007. pp. 47–77.
75. Burga AM, Fadare O, Lininger RA, Tavassoli FA. Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases. Virchows Arch. 2006;449:507–512. [PMC free article] [PubMed]
76. Macdonald G, Paltiel C, Olivotto IA, Tyldesley S. A comparative analysis of radiotherapy use and patient outcome in males and females with breastcancer. Ann Oncol. 2005;16:1442–1448. [PubMed]
77. Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85:629–639. [PubMed]
78. Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, Osborne MP, McKinnon WM. Current management of male breast cancer. A review of 104 cases. Ann Surg. 1992;215:451–457. [discussion 457–59] [PubMed]
79. Heller KS, Rosen PP, Schottenfeld D, Ashikari R, Kinne DW. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg. 1978;188:60–65. [PubMed]
80. Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, Naessens JM, O’Brien PC. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol. 1993;2:325–333. [PubMed]
81. Cutuli B, Dilhuydy JM, De Lafontan B, Berlie J, Lacroze M, Lesaunier F, Graic Y, Tortochaux J, Resbeut M, Lesimple T, Gamelin E, Campana F, Reme-Saumon M, Moncho-Bernier V, Cuilliere JC, Marchal C, DeGislain G, N’Guyen TD, Teissier E, Velten M. Ductal carcinoma in situ of the male breast. Analysis of 31 cases. Eur J Cancer. 1997;33:35–38. [PubMed]
82. Schuchardt U, Seegenschmiedt MH, Kirschner MJ, Renner H, Sauer R. Adjuvant radiotherapy for breast carcinoma in men: a 20-year clinical experience. Am J Clin Oncol. 1996;19:330–336. [PubMed]
83. Gradishar WJ. Male breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborn CK, editors. Disease of the Breast. Philedelphia: Lippincott Williams and Wilkins; 2000. pp. 661–667.
84. Weiderpass E, Ye W, Adami Ho, Vainio H, Trichopoulos D, Nyren O. Breast cancer risk in male alcoholics in Sweden. Cancer Causes Control. 2001;12:661–664. [PubMed]
85. Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet. 2000;355:1757–1770. [PubMed]
86. Gentilini O, Chagas E, Zurrida S, Intra M, De Cicco C, Gatti G, Silva L, Renne G, Cassano E, Veronesi U. Sentinel lymph node biopsy in male patients with early breast cancer. The Oncologist. 2007;12:512–525. [PubMed]
87. Gennari R, Curigliano G, Jereczek-Fossa BA, Zurrida S, Renne G, Intra M, Galimberti V, Luini A, Orecchia R, Viale G, Goldhrisch A, Veronesi U. Male breast cancer: a special therapeutic problem. Anything new? (Review) Int J Oncol. 2004;24:663–670. [PubMed]
88. Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvan chemotherapy in males with cancer of the breast. Am J Clin Oncol. 1987;10:55–60. [PubMed]
89. Izquierdo MA, Alonso C, De Andres l, Ojeda B. Male breast cancer. Report of a series of 50 cases. Acta Oncol. 1994;33:767–771. [PubMed]
90. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med. 1992;117:771–777. [PubMed]
91. Giordano SH, Perkins G, Garcia SM, et al. Male breast cancer: the M.D. Anderson experience with adjuvan therapy. Breast Cancer Res Treat. 2003;82:S42.
92. Hayes T. Pharmacotherapy for male breast cancer. Expert Opin Pharmacother. 2002;3:701–708. [PubMed]
93. Gomez-Raposo C, Zambrana Tevar F, Sereno Moyano M, Lopez Gomez M, Casado E. Male breast cancer. Cancer Treat Rev. 2010;36:451–457. [PubMed]
94. Di Lauro L, Pizzuti L, Barba M, Sergi D, Sperduti I, Mottolese M, Del Medico P, Belli F, Vici P, De Maria R, Maugeri-Saccà M. Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. Journal of Experimental and Clinical Cancer Research. 2015;34:26. [PMC free article] [PubMed]
95. Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol. 1998;24:548–52. [PubMed]
96. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004. 2004;101:51–57. [PubMed]
97. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: A population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232–9. [PMC free article] [PubMed]
98. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. [PubMed]
99. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinicalimplications. Proc Natl Acad Sci USA. 2001;98:10869–10874. [PubMed]
100. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502. [PubMed]
101. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes Marieke CH, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ. Molecular subtyping of male breast cancer by immunohistochemistry. Modern Pathology. 2012;25:398–404. [PubMed]
102. Leone J, Zwenger AO, Iturbe J, Vallejo CT, Leone BA. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015;152:601–609. [PubMed]
103. Nahleh Z. Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treatment Rev. 2006;32:101–105. [PubMed]
104. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, Hughes KS. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996;77:490–498. [PubMed]
105. Willsher PC, Leach IH, Ellis IO, Bourke JB, Blamey RW, Robertson JF. A comparison outcome of male breast cancer with female breast cancer. Am J Surg. 1997;173:185–188. [PubMed]
106. Guinee VF, Olsson H, Moller T, Shallenberger RC, van den Blink JW, Peter Z, Durand M, Dische S, Cleton FJ, Zewuster R, et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer. 1993;71:154–161. [PubMed]
107. Joshi MG, Lee AK, Loda M, Camus MG, Pedersen C, Heatley GJ, Hughes KS. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996;77:490–498. [PubMed]
108. Rayson D, Erlichman C, Suman VJ, Roche PC, Wold LE, Ingle JN, Donohue JH. Molecular markers in male breast carcinoma. Cancer. 1998;83:1947–1955. [PubMed]
109. Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res. 2009;11:R28. [PMC free article] [PubMed]
110. Yoney A, Kucuk A, Unsal M. Male breast cancer: a retrospective analysis. Cancer Radiotherapie. 2009;13:103–107. [PubMed]
111. Goyal A, Horgan K, Kissi M, Yiangou C, Sibbering M, Lansdown M, Newcombe RG, Mansel RE, Chetty U, Ell P, Fallowfield L, Kissin M. ALMANAC Trialists Group. Sentinel lymph node biopsy in male breast cancer patients. EJSO. 2004;30:480–483. [PubMed]

Articles from The Journal of Breast Health are provided here courtesy of Turkish Federation of Breast Diseases Societies